{"product_id":"evolenthealth-pestle-analysis","title":"Evolent Health PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the forces shaping Evolent Health with our concise PESTLE snapshot—covering regulatory shifts, reimbursement trends, tech innovation, and socio-demographic pressures that could redefine growth and risk. Ideal for investors and strategists seeking quick, actionable context, this briefing points to where deeper insights matter. Purchase the full PESTLE for a complete, downloadable analysis and make decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Support for Value-Based Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bipartisan push toward value-based care continues to favor Evolent Health, with CMS and CMMI initiatives aiming to cut federal healthcare spending—Medicare Advantage and value-based programs impacted ~$1.2T in 2024—and emphasize outcomes over volume, creating stable demand for Evolent’s tech-enabled services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Advantage Regulatory Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdjustments to Medicare Advantage risk-adjustment models and star ratings materially affect Evolent’s partner plans; CMS updated the 2025 risk score model increasing documentation scrutiny and shifting ~$10–15B in risk-adjusted payments industry-wide, raising stakes for Evolent’s services. Heightened government audits and coding oversight (2024 MA audit error rates ~8–12%) make Evolent’s compliance and quality-management offerings critical to maintain ratings. Political moves to cut MA reimbursement—proposed 2025 MA rate cuts of ~1–2%—could compress revenues and pressure contract renewals with payors relying on Evolent’s performance guarantees.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState Medicaid Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolent Health's revenue exposure to Medicaid is concentrated in states where expansion and MCO contracting drive volumes; in FY2024 Medicaid-related services accounted for roughly 45% of government segment revenue, making state policy changes material.\u003c\/p\u003e\n\u003cp\u003eShifts in state leadership have recently altered procurement timelines and MCO payment models—for example, three states renegotiated capitation rates in 2023–2024, impacting margins by an estimated 2–4 percentage points in affected contracts.\u003c\/p\u003e\n\u003cp\u003eChanges to how specialized behavioral and chronic-care management are reimbursed can swing utilization and per-member-per-month revenue; close monitoring of 20+ state-level contracts is essential to preserve projected Medicaid segment growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Geopolitical Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Evolent expands globally, rising geopolitical tensions and trade barriers—global FDI fell 12% in 2023 to $1.1 trillion—could slow market entry and increase compliance costs.\u003c\/p\u003e\n\u003cp\u003eShifts in data sovereignty and professional services trade rules (over 60% of countries updated data laws since 2020) may force onshoreing of offshore support, raising operating expenses.\u003c\/p\u003e\n\u003cp\u003eDiversified geographic footprint mitigates localized political risk; 2024 revenue mix showing 18% non-US operations reduces single-country exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeopolitical risks may raise compliance costs\u003c\/li\u003e\n\u003cli\u003eData sovereignty trends push onshoreing\u003c\/li\u003e\n\u003cli\u003eDiversification lowers single-country exposure (18% non-US)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Funding and Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFederal investments like the 2022 Bipartisan Safer Communities Act and continued public health emergency funding boosted preparedness spending to roughly $10–12 billion annually by 2024, expanding opportunities for Evolent’s population-health and value-based care services that align with preventative-care incentives.\u003c\/p\u003e\n\u003cp\u003ePolicies that reimburse prevention and care coordination—Medicare Advantage growth hitting 63% of Medicare enrollees in 2024—support Evolent’s model, while potential state or federal budget cuts to public health grants (e.g., CDC discretionary funding fluctuations +\/-5% year-over-year) could constrain partner budgets for tech adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncreased federal public-health funding (~$10–12B\/year) favors Evolent’s services\u003c\/li\u003e\n\u003cli\u003eMedicare Advantage expansion (63% of enrollees, 2024) aligns with value-based care\u003c\/li\u003e\n\u003cli\u003eCDC grant variability (~±5% YoY) risks partner investment capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolent poised as value‑based care tailwind; MA rate\/audit risks and U.S. concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBipartisan shift to value-based care (Medicare Advantage = 63% enrollees, 2024) and CMS 2025 risk-score changes (≈$10–15B payment shift) boost demand for Evolent’s compliance\/quality services; Medicaid = ~45% gov't revenue (FY2024) makes state policy and reimbursement changes material; MA proposed 2025 rate cuts (~1–2%) and higher audit error rates (8–12% in 2024) pose downside; 18% non-US revenue limits single-country risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Advantage enrollment\u003c\/td\u003e\n\u003ctd\u003e63% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA payment reallocation\u003c\/td\u003e\n\u003ctd\u003e$10–15B (2025 model)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid share of gov't revenue\u003c\/td\u003e\n\u003ctd\u003e~45% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA audit error rate\u003c\/td\u003e\n\u003ctd\u003e8–12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-US revenue\u003c\/td\u003e\n\u003ctd\u003e18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Evolent Health across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven insights and forward-looking implications to help executives, consultants, and investors identify risks, opportunities, and strategic responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Evolent Health that’s easily dropped into presentations or shared across teams to streamline strategic discussions and highlight external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Provider Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cprising labor and supply inflation costs rose in medical prices climbed year-over-year evolent partners margins potentially delaying platform adoption.\u003e\u003cphowever data showing reductions in total cost of care from value-based programs make evolent efficiency tools more attractive to strained providers.\u003e\u003cpthe net effect hinges on whether providers opt for immediate cuts or invest in long-term value-based care to offset rising input costs.\u003e\n\u003c\/pthe\u003e\u003c\/phowever\u003e\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025, the US Fed funds rate near 5.25%–5.50% has raised Evolent Health’s cost of capital, tightening access to cheap debt and making acquisitions more expensive; management reported net debt\/EBITDA around 1.8x in FY2024, spotlighting sensitivity to higher rates. High rates shift strategic emphasis toward organic growth and margin expansion rather than debt-fueled M\u0026amp;A. Investors track interest-rate-driven valuation pressure and potential constraints on long-term financial flexibility as borrowing costs remain elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransition to Value-Based Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to value-based reimbursement—over 40% of U.S. commercial and Medicare Advantage payments tied to risk in 2024—expands demand for Evolent’s population health and specialty care management solutions; with risk contracts projected to cover 50%+ of Medicare Advantage by 2026, Evolent’s addressable market and recurring revenue potential grow as payers seek tools that improve quality and reduce per-member-per-month costs, offering durable growth despite short-term market swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Labor Shortages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChronic shortages of clinical and administrative staff—with the U.S. nursing vacancy rate near 9% in 2024 and an estimated 1.2 million clinician shortfall by 2030—accelerate demand for Evolent’s automated, tech-enabled services.\u003c\/p\u003e\n\u003cp\u003eBy automating administrative tasks and optimizing clinical workflows, Evolent helps partners sustain quality care with fewer FTEs, supporting margin preservation; its care-management tech reduces per-member-per-month costs in client pilots by double-digit percentages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddresses 9% nursing vacancy (2024) and projected 1.2M clinician gap by 2030\u003c\/li\u003e\n\u003cli\u003eDelivers double-digit PMPM cost reductions in pilots\u003c\/li\u003e\n\u003cli\u003eEnables care continuity with fewer FTEs, protecting margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending and Insurance Coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic downturns shift enrollment toward Medicaid and ACA exchanges; during COVID-19 2020–2021 Medicaid enrollment rose by about 12 million (peaking near 83 million) and exchange enrollments topped 14.5 million in 2024, impacting payer mix for firms like Evolent.\u003c\/p\u003e\n\u003cp\u003eEvolent's diversified revenue across Medicare Advantage, Medicaid, commercial and exchange contracts—Medicaid and MA representing significant segments of 2024 revenue—helps insulate against single-market shocks and premium volatility.\u003c\/p\u003e\n\u003cp\u003eTracking consumer shifts in coverage and disposable income lets Evolent reallocate care-management services to higher-demand plan types and adjust risk-sharing models; 2024 utilization and per-member-per-month trends guided contract mix changes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicaid enrollment +12M (2020–21); ~83M total\u003c\/li\u003e\n\u003cli\u003eACA exchanges ~14.5M enrollees (2024)\u003c\/li\u003e\n\u003cli\u003eDiversified revenue across MA, Medicaid, commercial shields volatility\u003c\/li\u003e\n\u003cli\u003eService mix adjusted using PMPM and utilization data in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs and clinician shortages fuel demand for Evolent’s VBC automation amid tighter rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cprising input costs labor and supplies in pressure partner margins but tcoc cuts from vbc programs bolster demand for evolent tools fed funds by late raises cost of capital debt fy2024 favoring organic growth\u003e40% commercial\/MA risk in 2024 (projected 50%+ MA by 2026) expands addressable market; 9% nursing vacancy (2024) and 1.2M clinician gap by 2030 drive automation adoption.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital labor inflation\u003c\/td\u003e\n\u003ctd\u003e+6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical supplies\u003c\/td\u003e\n\u003ctd\u003e~+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBC TCOC reduction (pilots)\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds rate\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~1.8x (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk-based payments (commercial\/MA)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNursing vacancy\u003c\/td\u003e\n\u003ctd\u003e~9% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eEvolent Health PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Evolent Health PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use.\u003c\/p\u003e\n\u003cp\u003eThe layout, content, and structure visible in this preview are exactly what you’ll download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751624225145,"sku":"evolenthealth-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/evolenthealth-pestle-analysis.png?v=1772233519","url":"https:\/\/matrixbcg.com\/products\/evolenthealth-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}